NIH to study remdesivir-esque Gilead compound as potential COVID-19 treatment

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

GS-441524 has not yet been tested in human beings, however preliminary research study suggests it works to hinder viruses in a comparable method to remdesivir..

” Scientists in our Division of Preclinical Innovation evaluated the literature and agree that this compound merits further exploration,” the National Center for Advancing Translational Sciences composed in its letter. We expect to carry out these studies quickly and make the results readily available to the research neighborhood for additional consideration.”.

” Scientists in our Division of Preclinical Innovation examined the literature and concur that this substance merits even more exploration,” the National Center for Advancing Translational Sciences composed in its letter. We expect to perform these research studies rapidly and make the results readily available to the research neighborhood for further factor to consider.”.

More posts on drug store: Novartis drug earns FDA approval to deal with MS6 current drug, gadget recallsFDA grants emergency situation approval for convalescent plasma as COVID-19 treatment.

The National Institutes of Health will carry out independent trials examining the efficiency of GS-441524, a Gilead drug substance that bears resemblances to its remdesivir, in dealing with COVID-19.

© Copyright ASC COMMUNICATIONS 2020.

Katie Adams –
Monday, August 24th, 2020
Print|Email.

The NIHs National Center for Advancing Translational Sciences announced these plans in an Aug. 20 letter to 2 MD Anderson Cancer Center researchers and 3 members of Public Citizens Health Research Group, all of whom had actually just recently composed to the NIH and FDA advising them to pressure Gilead into running studies on the compound.